KR20060017545A - 테트라하이드로카르바졸 유도체 및 이들의 약제학적 용도 - Google Patents

테트라하이드로카르바졸 유도체 및 이들의 약제학적 용도 Download PDF

Info

Publication number
KR20060017545A
KR20060017545A KR1020057023781A KR20057023781A KR20060017545A KR 20060017545 A KR20060017545 A KR 20060017545A KR 1020057023781 A KR1020057023781 A KR 1020057023781A KR 20057023781 A KR20057023781 A KR 20057023781A KR 20060017545 A KR20060017545 A KR 20060017545A
Authority
KR
South Korea
Prior art keywords
tetrahydro
amine
bromo
carbazol
carbazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057023781A
Other languages
English (en)
Korean (ko)
Inventor
샤론 데이비스 보그스
크리스트잔 에스. 굿문드슨
리아 디'오로라 리차드슨
폴 리차드 세바하
Original Assignee
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미스클라인 비참 코포레이션 filed Critical 스미스클라인 비참 코포레이션
Publication of KR20060017545A publication Critical patent/KR20060017545A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
KR1020057023781A 2003-06-10 2004-06-07 테트라하이드로카르바졸 유도체 및 이들의 약제학적 용도 Withdrawn KR20060017545A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47725103P 2003-06-10 2003-06-10
US60/477,251 2003-06-10
US49782303P 2003-08-26 2003-08-26
US60/497,823 2003-08-26

Publications (1)

Publication Number Publication Date
KR20060017545A true KR20060017545A (ko) 2006-02-23

Family

ID=33555453

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057023781A Withdrawn KR20060017545A (ko) 2003-06-10 2004-06-07 테트라하이드로카르바졸 유도체 및 이들의 약제학적 용도

Country Status (16)

Country Link
US (1) US7351733B2 (https=)
EP (1) EP1654228B1 (https=)
JP (1) JP2007501284A (https=)
KR (1) KR20060017545A (https=)
AT (1) ATE411981T1 (https=)
AU (1) AU2004247676A1 (https=)
BR (1) BRPI0411085A (https=)
CA (1) CA2528321A1 (https=)
CO (1) CO5660287A2 (https=)
DE (1) DE602004017326D1 (https=)
ES (1) ES2314446T3 (https=)
IL (1) IL171974A0 (https=)
MA (1) MA27880A1 (https=)
NO (1) NO20055741L (https=)
RU (1) RU2318810C2 (https=)
WO (1) WO2004110999A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101671484B1 (ko) 2016-07-21 2016-11-01 김정환 오셀타미비르(Oseltamivir)를 포함하는 인유두종 바이러스 치료용 약학적 조성물
KR20240075403A (ko) 2022-11-22 2024-05-29 이경엽 알칼로이드 함유 인유두종 바이러스 감염의 예방 또는 치료용 조성물
KR20240075422A (ko) 2022-11-22 2024-05-29 이경엽 인유두종 바이러스 감염에 의한 후두유두종의 예방 또는 치료용 조성물

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622494B2 (en) 2003-08-26 2009-11-24 Smithkline Beecham Corporation Chemical compounds
MXPA06010543A (es) 2004-03-15 2007-03-26 Ptc Therapeutics Inc Derivados de carbolina utiles en la inhibicion de la angiogenesis.
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
WO2006012310A2 (en) * 2004-06-25 2006-02-02 Genzyme Corporation Carbazole derivatives for treating polycystic kidney disease
JP2008520675A (ja) * 2004-11-22 2008-06-19 スミスクライン ビーチャム コーポレーション Ｈｃｖ阻害剤
US8143257B2 (en) * 2004-11-23 2012-03-27 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting VEGF production
WO2007002051A1 (en) * 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
WO2013139929A1 (en) * 2012-03-22 2013-09-26 Ludwig-Maximilians-Universität München Novel means and methods for treating diseases of the central nervous system, metabolic and cardiac diseases and aging
WO2013177241A1 (en) 2012-05-22 2013-11-28 Trustees Of Dartmouth College Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use
EP2690091A1 (en) 2012-07-25 2014-01-29 Studiengesellschaft Kohle mbH Process for preparing substituted indole derivatives
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
WO2021183980A1 (en) * 2020-03-13 2021-09-16 Fmc Corporation Substituted pyrimidines and triazines as herbicides
CN113995758B (zh) * 2021-11-04 2023-06-02 中山大学 咔唑-嘧啶衍生物在制备治疗抗肿瘤药物中的应用
EP4725481A1 (en) * 2024-10-10 2026-04-15 Leibniz-Institut für Virologie 1,2,3,4-tetrahydrocarbazole derivatives for use in treating an adenoviral infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE507797C (de) * 1927-05-14 1930-09-20 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von 1-Aminocarbazol und seinen Derivaten
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
US5100891A (en) 1991-01-18 1992-03-31 Hoechst-Roussel Pharmaceuticals Inc. Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[B]indoles and related compounds
CA2106642C (en) * 1992-10-14 2005-08-16 Peter Bod Carbazolone derivatives and process for preparing the same
US6045398A (en) * 1995-07-10 2000-04-04 International Business Machines Corporation Battery accepting unit and battery pack
GB0015904D0 (en) * 2000-06-28 2000-08-23 Hoffmann La Roche Inhibitors of HPV E1 helicase enzyme
NZ533430A (en) * 2001-12-14 2005-12-23 Zentaris Gmbh Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101671484B1 (ko) 2016-07-21 2016-11-01 김정환 오셀타미비르(Oseltamivir)를 포함하는 인유두종 바이러스 치료용 약학적 조성물
KR20240075403A (ko) 2022-11-22 2024-05-29 이경엽 알칼로이드 함유 인유두종 바이러스 감염의 예방 또는 치료용 조성물
KR20240075422A (ko) 2022-11-22 2024-05-29 이경엽 인유두종 바이러스 감염에 의한 후두유두종의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
US20060161002A1 (en) 2006-07-20
EP1654228A1 (en) 2006-05-10
AU2004247676A1 (en) 2004-12-23
ATE411981T1 (de) 2008-11-15
RU2005138124A (ru) 2006-07-10
IL171974A0 (en) 2006-04-10
NO20055741D0 (no) 2005-12-05
DE602004017326D1 (de) 2008-12-04
US7351733B2 (en) 2008-04-01
CO5660287A2 (es) 2006-07-31
WO2004110999A1 (en) 2004-12-23
NO20055741L (no) 2006-01-06
BRPI0411085A (pt) 2006-07-25
JP2007501284A (ja) 2007-01-25
MA27880A1 (fr) 2006-05-02
ES2314446T3 (es) 2009-03-16
RU2318810C2 (ru) 2008-03-10
CA2528321A1 (en) 2004-12-23
EP1654228B1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
KR20060017545A (ko) 테트라하이드로카르바졸 유도체 및 이들의 약제학적 용도
US20080103164A1 (en) Useful compounds for hpv infection
CN105934425A (zh) Ebna1抑制剂和其使用方法
EP1646610B1 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2022148442A1 (zh) 6-取代磷酰基喹唑啉类衍生物及其制备方法和用途
US7622494B2 (en) Chemical compounds
US20090156621A1 (en) Hcv inhibitors
CN114401935B (zh) 离子通道拮抗剂/阻断剂及其用途
CN110041272B (zh) 2-(2-氯苯基)喹唑啉-4(3h)-酮类衍生物及其制备方法和用途
ZA200509905B (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
CN115772170A (zh) 一种吡唑并[1,5-a]吡啶衍生物及其制备方法和应用
ZA200509902B (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
MXPA05013425A (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
US20240043423A1 (en) Compounds and methods for treatment of hedgehog pathway associated conditions
CN115677703A (zh) 吡啶酮类化合物及其用途
MXPA05013424A (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2019233438A1 (zh) 一种激酶选择性抑制剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051210

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid